JP7539892B2 - 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素ｉ（ｉｒｅｉアルファ）の阻害剤としてのピリド－ピリミジノン化合物及びプテリジノン化合物 - Google Patents

癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素ｉ（ｉｒｅｉアルファ）の阻害剤としてのピリド－ピリミジノン化合物及びプテリジノン化合物 Download PDF

Info

Publication number
JP7539892B2
JP7539892B2 JP2021539020A JP2021539020A JP7539892B2 JP 7539892 B2 JP7539892 B2 JP 7539892B2 JP 2021539020 A JP2021539020 A JP 2021539020A JP 2021539020 A JP2021539020 A JP 2021539020A JP 7539892 B2 JP7539892 B2 JP 7539892B2
Authority
JP
Japan
Prior art keywords
oxo
amino
isopropyl
pyrimidin
dihydropyrido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021539020A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022517189A5 (https=
JPWO2020142612A5 (https=
JP2022517189A (ja
Inventor
ブラウン，マリー－ガブリエル
カスタネード，ジョージェット
ギボンズ，ポール
ルドルフ，ヨアヒム
ヴェルニエ，ウィリアム
ビバリッジ，ラムジー
ウー，ヤオ
ウー，グオション
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2022517189A publication Critical patent/JP2022517189A/ja
Publication of JP2022517189A5 publication Critical patent/JP2022517189A5/ja
Publication of JPWO2020142612A5 publication Critical patent/JPWO2020142612A5/ja
Application granted granted Critical
Publication of JP7539892B2 publication Critical patent/JP7539892B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021539020A 2019-01-03 2020-01-02 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素ｉ（ｉｒｅｉアルファ）の阻害剤としてのピリド－ピリミジノン化合物及びプテリジノン化合物 Active JP7539892B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/070275 2019-01-03
CN2019070275 2019-01-03
CNPCT/CN2019/081673 2019-04-08
CN2019081673 2019-04-08
PCT/US2020/012058 WO2020142612A1 (en) 2019-01-03 2020-01-02 Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases.

Publications (4)

Publication Number Publication Date
JP2022517189A JP2022517189A (ja) 2022-03-07
JP2022517189A5 JP2022517189A5 (https=) 2023-01-04
JPWO2020142612A5 JPWO2020142612A5 (https=) 2023-01-04
JP7539892B2 true JP7539892B2 (ja) 2024-08-26

Family

ID=69400641

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021539020A Active JP7539892B2 (ja) 2019-01-03 2020-01-02 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素ｉ（ｉｒｅｉアルファ）の阻害剤としてのピリド－ピリミジノン化合物及びプテリジノン化合物

Country Status (6)

Country Link
US (1) US12344603B2 (https=)
EP (1) EP3941919B1 (https=)
JP (1) JP7539892B2 (https=)
CN (1) CN113508115A (https=)
TW (1) TWI748317B (https=)
WO (1) WO2020142612A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI831829B (zh) 2018-09-12 2024-02-11 美商建南德克公司 苯氧基-吡啶基-嘧啶化合物及使用方法
JP7539892B2 (ja) 2019-01-03 2024-08-26 ジェネンテック， インコーポレイテッド 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素ｉ（ｉｒｅｉアルファ）の阻害剤としてのピリド－ピリミジノン化合物及びプテリジノン化合物
CN113795307A (zh) * 2019-02-18 2021-12-14 基因泰克公司 吡啶并嘧啶基化合物及其使用方法
PL4073065T3 (pl) 2019-12-10 2025-05-19 F. Hoffmann-La Roche Ag Nowe pochodne metylochinazolinonu
MX2023005747A (es) 2020-11-18 2023-07-28 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos.
EP4263541A1 (en) * 2020-12-18 2023-10-25 F. Hoffmann-La Roche AG New aryl-pyrido-pyrimidin-one derivatives
WO2022129259A1 (en) 2020-12-18 2022-06-23 F. Hoffmann-La Roche Ag New quinazolinone derivatives
WO2022261250A1 (en) 2021-06-08 2022-12-15 C4 Therapeutics, Inc. Therapeutics for the degradation of mutant braf
WO2023046114A1 (zh) * 2021-09-24 2023-03-30 华东理工大学 蝶啶酮衍生物及其应用
KR20240113496A (ko) 2021-12-03 2024-07-22 데시페라 파마슈티칼스, 엘엘씨. Gcn2 및 perk 키나아제 억제제로서의 헤테로고리 화합물
WO2024131893A1 (en) * 2022-12-22 2024-06-27 Shanghai Yi Zhong Xing Biotechnology Co., Ltd. IRE1α SMALL MOLECULE INHIBITORS
US12573866B2 (en) 2023-11-17 2026-03-10 Exro Technologies Inc. Battery system for operating point control of power systems

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008504281A (ja) 2004-06-23 2008-02-14 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
JP2010503701A (ja) 2006-09-14 2010-02-04 デシファラ ファーマスーティカルズ， エルエルシー 増殖性疾患の治療に有用なキナーゼ阻害剤
JP2010509265A (ja) 2006-11-09 2010-03-25 エフ．ホフマン−ラ ロシュ アーゲー キナーゼ阻害剤としての置換６−フェニル−ピリド［２，３−ｄ］ピリミジン−７−オン誘導体及びそれの使用方法
JP2013518904A (ja) 2010-02-05 2013-05-23 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
WO2014179498A1 (en) 2013-04-30 2014-11-06 Genentech, Inc. Serine/threonine kinase inhibitors
WO2018102751A1 (en) 2016-12-02 2018-06-07 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors
WO2018222918A1 (en) 2017-06-01 2018-12-06 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors
WO2018222917A1 (en) 2017-06-01 2018-12-06 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
EP1409487A1 (en) * 1999-09-15 2004-04-21 Warner-Lambert Company Llc Pteridinones as kinase inhibitors
WO2002018380A1 (en) 2000-08-31 2002-03-07 F. Hoffmann-La Roche Ag 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation
WO2004063195A1 (en) * 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Pyridopyrimidine kinase inhibitors
AU2004279427B2 (en) * 2003-10-08 2008-07-03 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1751136B1 (en) 2004-05-07 2014-07-02 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
EP1831215A1 (en) * 2004-11-23 2007-09-12 Ranbaxy Laboratories Limited Pyrido[2,3-d]pyrimidines as anti-inflamatory agents
EP1846403A1 (en) * 2005-02-02 2007-10-24 Ranbaxy Laboratories Limited Azabicyclo derivatives as anti-inflammatory agents
US7868177B2 (en) 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
US20090312321A1 (en) * 2006-05-15 2009-12-17 Irm Llc Compositions and methods for fgf receptor kinases inhibitors
CA2672518A1 (en) 2006-12-22 2008-07-03 Novartis Ag Organic compounds and their uses
CN102264728B (zh) 2008-09-15 2015-02-04 加利福尼亚大学董事会 用于调节ire1、src和abl活性的方法和组合物
MX2014005296A (es) * 2011-11-04 2014-08-27 Afraxis Holdings Inc Inhibidores de pak para el tratamiento del sindrome del x fragil.
WO2013090840A1 (en) 2011-12-15 2013-06-20 Gilead Sciences, Inc. 2 -amino- pyrido [3, 2 -d] pyrimidine derivatives as hcv inhibitors
MX2015003874A (es) 2012-09-26 2015-12-16 Univ California Modulacion de ire1.
WO2014179496A1 (en) * 2013-04-30 2014-11-06 Afraxis Holdings, Inc. Serine/threonine kinase inhibitors
WO2014182829A1 (en) * 2013-05-09 2014-11-13 Principia Biopharma Inc. Quinolone derivatives as fibroblast growth factor inhibitors
AR111281A1 (es) 2017-03-17 2019-06-26 Genentech Inc Compuestos de pirimidinil-piridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
US10392367B2 (en) 2017-06-01 2019-08-27 Quentis Therapeutics, Inc. IRE1 small molecule inhibitors
TWI831829B (zh) 2018-09-12 2024-02-11 美商建南德克公司 苯氧基-吡啶基-嘧啶化合物及使用方法
EP3891137B1 (en) 2018-12-03 2024-10-09 Cornell University Ire1 small molecule inhibitors
JP7539892B2 (ja) 2019-01-03 2024-08-26 ジェネンテック， インコーポレイテッド 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素ｉ（ｉｒｅｉアルファ）の阻害剤としてのピリド－ピリミジノン化合物及びプテリジノン化合物
US10927111B2 (en) 2019-05-03 2021-02-23 Kinnate Biopharma Inc. Inhibitors of RAF kinases
KR102396930B1 (ko) 2020-01-15 2022-05-12 한국과학기술연구원 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008504281A (ja) 2004-06-23 2008-02-14 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
JP2010503701A (ja) 2006-09-14 2010-02-04 デシファラ ファーマスーティカルズ， エルエルシー 増殖性疾患の治療に有用なキナーゼ阻害剤
JP2010509265A (ja) 2006-11-09 2010-03-25 エフ．ホフマン−ラ ロシュ アーゲー キナーゼ阻害剤としての置換６−フェニル−ピリド［２，３−ｄ］ピリミジン−７−オン誘導体及びそれの使用方法
JP2013518904A (ja) 2010-02-05 2013-05-23 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
WO2014179498A1 (en) 2013-04-30 2014-11-06 Genentech, Inc. Serine/threonine kinase inhibitors
WO2018102751A1 (en) 2016-12-02 2018-06-07 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors
WO2018222918A1 (en) 2017-06-01 2018-12-06 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors
WO2018222917A1 (en) 2017-06-01 2018-12-06 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorg. Med. Chem. Lett.，2012年，22，3387-3391

Also Published As

Publication number Publication date
EP3941919A1 (en) 2022-01-26
TWI748317B (zh) 2021-12-01
WO2020142612A1 (en) 2020-07-09
CN113508115A (zh) 2021-10-15
US20230047209A1 (en) 2023-02-16
US12344603B2 (en) 2025-07-01
JP2022517189A (ja) 2022-03-07
TW202039466A (zh) 2020-11-01
EP3941919B1 (en) 2025-12-24

Similar Documents

Publication Publication Date Title
JP7539892B2 (ja) 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素ｉ（ｉｒｅｉアルファ）の阻害剤としてのピリド－ピリミジノン化合物及びプテリジノン化合物
JP7746278B2 (ja) Ｂｒｄ９の標的分解のための化合物
JP7611154B2 (ja) ピリド－ピリミジニル化合物及び使用の方法
US12071425B2 (en) Phenoxy-pyridyl-pyrimidine compounds and methods of use
JP2024523839A (ja) 突然変異体ｂｒａｆを分解する療法薬
JP2020514377A (ja) ピリミジニル−ピリジルオキシ−ナフチル化合物及びｉｒｅ１関連疾患及び障害を治療する方法
EP3983400B1 (en) Quinazolinyl compounds and methods of use
CN112689528B (zh) 嘧啶基-杂芳氧基-萘基化合物和使用方法
HK40061403A (en) Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases
HK40051987A (en) Pyrimidinyl-heteroaryloxy-naphthyl compounds and methods of use
HK40062380A (en) Quinazolinyl compounds and methods of use
HK40051987B (zh) 嘧啶基-杂芳氧基-萘基化合物和使用方法
HK40056588A (en) Pyrido-pyrimidinyl compounds and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221221

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240612

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240814

R150 Certificate of patent or registration of utility model

Ref document number: 7539892

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150